Aster Insights
Rob Rounbehler has a strong background in research, with experience spanning multiple prestigious institutions. Rob began their career as a Graduate Research Assistant at MD Anderson Cancer Center in 1998. From 2003 to 2007, they worked as a Postdoctoral Research Associate at St. Jude Children's Research Hospital. Rob then moved on to The Scripps Research Institute - Florida campus, where they held the positions of Postdoctoral Research Associate and Research Scientist from 2007 to 2014. In 2014, they joined Moffitt Cancer Center as a Research Scientist and later became a Research Instructor. Most recently, in 2022, they became a Principal Scientist at Aster Insights.
Rob Rounbehler completed their Bachelor of Science degree in Microbiology at Kansas State University from 1994 to 1998. Rob then pursued their Ph.D. in Molecular and Environmental Carcinogenesis at The University of Texas Health Science Center at Houston (UTHealth Houston), which they completed from 1998 to 2003.
Aster Insights
We believe that personalized medicine starts with a complete view of an individual across their lifetime. Our company was founded in 2006 on the unique principle that informed consent from patients entrusting us with a lifetime connection to their health information, paired with deep partnerships across academia and the life sciences industry, would unlock critical advances in curing cancer. Aster Insights leads the Oncology Research Information Exchange Network (ORIEN®), a consortium of the nation’s leading academic cancer centers that conduct Total Cancer Care®, the world’s largest and longest running observational research study in oncology. TCC® serves as the foundation for novel insights that power oncology breakthroughs. As a long-time innovator in oncology, Aster Insights has world-class expertise in accelerating the life cycle of oncology medical product development. Our solutions are based on scientific and clinical intelligence and strengthened by our unique partnership with patients, academia, and industry. We empower our partners to uncover new targets and biomarkers, enhance cancer detection, deepen our understanding of new treatments, discover new indications, and accelerate clinical trials. Together, we are changing the way cancer is studied, treated, and prevented.